# Financial Results Report

Q2 FY06/2024

## OLBA HEALTHCARE HOLDINGS, Inc.

(Former KAWANISHI HOLDINGS CO., LTD.)

(Ticker: 2689)

This presentation includes machine translation.

Please consider that some content may not be perfectly accurate or contextually appropriate.



## **Condolence to the 2024 Noto Peninsula Earthquake**

We would like to express our sincere condolences to those affected by the Noto Peninsula Earthquake.

I pray for the earliest possible recovery and return to a peaceful life.

### **Contents**

- Corporate Philosophy and Sustainability
- Q2 FY6/2024 Results
- Forecasts and Basic policy on dividends for FYE June 2024
- Medium-term business plan
- Reference Materials


Corporate Philosophy • Sustainability-related





# Formulation of Basic ESG Policy

# Formulated the Basic ESG Policy based on the Employee Charter



### **Environment (environmental)**

- Aiming to Realize a Sustainable Society by Considering Environmental Impact Reduction and Environmental Conservation
- $\Rightarrow$  Calculate greenhouse gas emissions and energy consumption, and implementation efforts to reduce environmental impact

### Social (Social)

• Aiming for Diversity in Human Resources and Working Styles, and Employees Being Healthy and Vibrant

**Promoting Work Style Reforms to Continue Working** 

### **Governance** (Governance)

- Fulfill responsibilities to employees, customers, business partners, and local residents in response to the mandate of shareholders
- Ensuring Management Transparency, Efficiency, and Soundness
- As a holding company of the Group, strive to increase the value of the Group

# **ESG** Initiatives (S: Society)

### **Investing in Human Capital and Working Style Reform**



- Improvement of employee treatment  $\Rightarrow$  Periodic salary increase + about 3% to 4% for bears
- Male employees taking childcare leave  $\Rightarrow$  Increasing trend
- Introduction of flextime and telecommuting, and promotion of "Sansei" campaign
  - $\Rightarrow$  Improving the work environment and organizational culture

### **Initiatives for Health Management**

- Certification of 2023 Excellent Health and Productivity Management Corporation (Large Enterprise)
- Establishment of Health Management Promotion Committee

## **Initiatives for Society**

Provision of safe and high-quality medical and nursing care equipment and services

- Stable supply of medical equipment
- Response to Natural Disasters and Pandemics
- Development of human resources who can contribute to resolve customer issues




### Continued emphasis on human resource education

Systematic human resource development and acquisition of expertise

OLBA Academy, a 30-year-old internal training system

Set opportunities to learn according to employee stages

- Enhance employee engagement
- Sources of competitive advantage



## **SDGs** (Sustainable Development Goals)

## **OLBA Six Priority Targets**



In countries around the world by 2030 17 development objectives to be achieved (United Nations)













-M/€









₫"



ħ

12 つくる責任 つかう責任

CO

### **Connecting People and** the Future

Connecting us to the future



Mission




Advanced medical devices **Development/intro** duction



Acknowledge the difference Respect



In medical and nursing care Not to stop



**Exercise** capabilities Can do Creating an **Environment** 



Medicalengineering collaboration Strengthened a strengthening

## **CSR Initiatives: Community-Based Social Contributions**

# Working together with local residents to create a future conducive to regional development and revitalization

### Faziano Okayama Club sponsor

Established in 2006 as Okayama Prefecture's first professional soccer club Entered J2 League in 2009



# Okayama TEC PLANTER Partner companies

With the creation of new businesses based on technologies originating in Okayama

Venture development and support



### Okayama Rivets Team sponsor

Male Table Team established in 2018
The national T league the national T league
Participated in



# Ohara museum of art Official partner



Established in 1930 in Kurashiki City, Okayama Prefecture

Japan's first private art museum focusing on western art

10

# FYE June 2024 Overview of Results for 2nd quarter FY3/16



## **Consolidated Financial Results for the Second Quarter of Fiscal 2024**

### Record high net sales in the interim financial results

	JPYmn	Comparison with budget	YoY
Sales	57,466	△0.5%	+7.0%
Gross profit	6,430	△2.4%	+4.0%
Sales GPM	11.19%		
SG&A expenses	5,683	△2.6%	+6.7%
Operating profit	746	△0.8%	Δ12.5%
Recurring profit	746	△1.6%	Δ13.2%
Net profit attributable to owners of parent	486	△0.2%	Δ11.2%

Quarterly net income per share 81.01 yen

[Factors behind the decrease in operating income] (YoY)

- Investment in human capital (salary base pay increase)
- Reinforcing personnel to strengthen the organizational structure
  - To invest in promoting DX

### Impact of New Corona Infectious Disease, Inflation, and Yen Depreciation

- The number of operations has generally recovered to pre-corona levels
  - Increase the rate of vaccination, take measures against infectious diseases at hospitals, change to 5 communicable diseases, etc.
    - Corona-related product demand trending downward
- Increase in purchase prices due to global inflation and depreciation of the yen
  - · Prices of medical devices, which have many overseas products, are on an upward trend
  - Implemented measures to expand sales activities and improve purchasing
  - Progress in passing on these costs to sales prices, ensuring a certain level of profit

Number of operations recovered until before Corona Consumables sales up, but corona-related demand paused

# [Interim] Medical Devices and Consumables

## Total partners in the medical field

JPYmn	Act.	Comparison with budget	YoY	
Sales	54,284	△1.1%	+7.1%	
<b>Operating</b> profit	668	Δ2.1%	△9.0%	







JPYmn	Sales Results **2	YoY
Kawanishi Corporation	36,364	+6.4%
Sansei Medical Materials Co., Ltd.	13,195	+11.8%
Nikko Medical Materials Co., Ltd.	5,327	+4.0%

**X1** Net sales (including changes from budget and changes from the previous fiscal year)

include intersegment sales

14

**<sup>\*\*2</sup>** Sales results of individual companies include the amount of transactions between group companies

## [Interim] Medical Equipment Business Consumables

### Sales ¥48.3 billion up 6.6% year on year

Millions of yen

<b>Product Classification</b>	Sales	YoY	Points of sub-segments
Surgery-related consumables	24,580	+5.4%	GI endoscopes +26.0%, anesthesia +14.7% Surgery +11.6%, anti-infective △ 10.9%
Orthopedic consumables	12,803	+5.5%	Spine +14.3%, trauma, sports, arthroscopes +4.5% Artificial Joints +2.0%
Cardiovascular- consumables	10,980	+10.6%	Cardiac and Vascular Surgery +18.6%, Catheter ABL*+17.0%

<sup>\*</sup> ABL: Therapy in which a portion of the heart is catheterized for a tachyarrhythmia, such as auricular fibrillation, to be ablated or frozen



Johnson & Johnson From our website (https://www.jnj.co.jp/)



### **Artificial knee joint**

Zimmer Biomet website Than https://www.zimmerbiomet.com/ja)



# [Interim] Medical device business-equipment and fixtures

### Net sales ¥6.9 billion up 18.9% year on year





#### **Points of Equipment Sales**

- ◆ Year-on-year increase due to strengthened discovery of capital investment projects
- **♦**Strong sales of automated payment machines for clinics
  - Pulmotor
  - Endoscopic surgical system
  - Operation microscope

- Ultrasonic diagnostic equipment
- HAEMODIALYSIS EQUIPMENT
- Vital signs monitor
- Knee joint Surgery Support

#### **Robotic**



With analysis function

Vital signs monitor



**Pulmotor** 


16

Fukuda Electronic Website From (https://www.fukuda.co.jp/)

Philips website Than https://www.philips.co.jp/healthcare) ©OLBA HEALTHCARE HOLDINGS, I

# [Interim] SPD business

JPYmn	Act.	Comparison with budget	YoY
Sales	2,590	Δ1.1%	+0.9%
Operating profit	52	+38.6%	<b>▲</b> 46.5%



- **♦** Review of commodity management service fees
- **♦** Decreased due to lost orders and decreased demand for infection control products.
- **♦** SG&A expenses increased due to higher fuel costs and higher personnel costs.



70 direct

3 franchise









Goods management

Purchasing management

Information management

\*Net sales (including changes from budget and changes from the previous fiscal year) include intersegment sales

# [Interim] Nursing Care Products business


JPYmn	Act.	Comparison with budget	YoY
Sales	1,317	+1.7%	+5.7%
Operating profit	101	△5.3%	+11.1%

Nursing Care Products [2.3%]

Sales
% of total

- **♦** Continued demand for home medical care and in-home nursing care
- **♦** Mainstay nursing care product rentals up 4.7% YoY
- **♦** Improved rental margins





<sup>\*</sup>Net sales (including changes from budget and changes from the previous fiscal year) include intersegment sales

18

©OLBA HEALTHCARE HOLDINGS, Inc

# FYE June 2024 results forecast Basic policy on dividends




# **Consolidated Financial Forecasts for the Fiscal Year Ending June 2024**

### All-time highs for net sales, operating income, and ordinary income

(JPYmn)	Forecast	2023/6 Act.	Change
Sales	118,386	110,472	+7.2%
Gross profit	13,872	12,954	+7.1%
Sales GPM	11.72%	11.73%	Δ0.01
SG&A expenses	11,672	10,803	+8.0%
Operating profit	2,200	2,151	+2.3%
Recurring profit	2,209	2,158	+2.4%
Net income attributable to owners of the parent	1,451	1,414	+2.7%

Net income per share  $\mathbf{Y}$  240.69

# Factors behind Changes in Operating Income for the Fiscal Year Ended June 2024



## **Consolidated Financial Results [Net Sales]**




Half-year Full year

FYE June 2021

Half-year Full year

FYE June 2020



Half-year Full year

**FYE June 2022** 

Half-year Full year

FYE June 2023


Half-year Full year

FYE June 2024

# **Consolidated Financial Results [Operating Income]**

FYE June 2024 Forecast of ¥2.2 billion (+2.3% YoY)

Full-year operating income increased for the fourth consecutive year and reached a record high




# Basic Policy on Dividends (Change on October 31, 2023)

The first basic policy was changed from "continuing stable dividends" to "aiming to increase or maintain dividends."

① Aiming to increase or maintain dividends

- FY6/24 forecast is JPY70
- 2 We will endeavor to retain internal reserves for growth investments.



<sup>\*\*</sup>For details of the change in dividend policy, please refer to the "Notice of Changes in Dividend Policy" announced on October 31, 2023.

# Financial indicators we emphasize

- ✓ Sales
- **✓** Operating profit
- **✓ ROE** =(Return on Equity)

x 100%

Shareholders' equity

**Profitability** improvement

Aiming to improve PBR by improving profitability, promoting new businesses, etc.

$$PBR = PER \times ROE$$

 $= \mathbf{x}$ 

Market capitalization

**Net income** 

### Dialogue with the market

- Upstream Strategy
- New businesses
- Overseas expansion

Fostering expectations
for growth


### **Net income**

Shareholders' equity

**Profitability** improvement

25

# Profitability analysis of the cost and capital current of equity status



<sup>\*</sup>Reference value for calculating cost of equity

<sup>•</sup> Risk-free rate: 10-year JGB yields, β value: about 0.8, market risk premium: about 7%

# Medium-term business plan




### Domestic market size of medical devices

### Stable market growth despite policies to curb medical costs

In fiscal 2023, Forecast of ¥3,774 trillion

- Recovering from the Impact of the New Corona and Stable Market Expansion
- · Market expansion due to increase in number of surgeries and introduction of new products




## Medium-term management plan

### Key Points of the 2024/6-2026/6 Medium-Term Management Plan



In the next 100 years
For
Building Foundations

Through the sharing of employee charters Sense of unity and empathy toward business



**FYE June 2026 Targets** 

Net sales ¥127.0 billion Operating income 26 Billions

# Reforming by Reform by promotion office


**Integrated logistics syste Develop Web order application** started operation To provide new value Streamlinin CRM g of regular construction operations **Introduction of business card Expansion of RPA utilization** management system Developmen **Democratiz** t of DX ation of the human system resources

Use of no-code tools

Education for all promotion officers and employees at each operating company

# **DX** Initiatives ① Development of **DX** Human Resources

# **Human Resource Development: Conducted DX literacy training for all employees**



# **DX Initiatives 2 Unique Electronic Catalogue**

• Utilization of proprietary electronic catalogue "MedTag"



- Rapid and reliable provision of information required by customers
- Posted 450000 of the total 850000 medical devices and supplies
   (Almost all products that are normally distributed)
- Unique tagging to support a wide variety of searches



Considering offering to medical institutions
(laying the groundwork for e-commerce)

# **DX** Initiatives ③ Logistics Innovation

• Operation of Li-Flo, an integrated logistics system

Started operation in September 2022 sequentially from the Kawanishi base of the operating companies

⇒ Expand of the system to the entire group



# Reinforcement in inventory control

Management of packaging

style

• Simple warehouse transfer

# To reinforce quality management

- Expiration control
- Management of sample

products, etc.

# Streamlining of lending business

- Handy and used sales
- Short-term external

inventory

### [Effects at introduction sites]

- Efficient product pick by scanning bar codes
- Efficiency of delivery slip output through system linkage
- Reduction of inventory time



# Clinic target towards new business business

### **Automatic payment machine Temasac sales for clinics**

•Introduction results from July to December 2023: 100 units (YoY +47 units)



### Entered into a business alliance with DVx

Entered into a business alliance agreement with the company for the next 100 years

### **Counterparty for business alliance**

- DIVEX CO., LTD (Securities code: 3079 Sales: 47.4 billion yen)
- A trading company that manufactures and sells medical equipment, with a focus on the cardiovascular field
  - Nationwide sales offices mainly in the Kanto region

Expansion into major metropolitan areas

つなぐ、人と未来。

### Details of consideration of business alliance, etc.

- Reduce costs by streamlining purchasing and logistics
- Expand sales and improve profitability through sales collaboration
- Information exchange on needs and seeds in medical/industrial collaboration
- Promotion of DX through operation and joint use of informationsystems



**\*\* For details on the signing of a business alliance agreement with DVX Corporation announced on March 15, 2023 Please refer to the Notice. The above sales figures are for the year ended March 31, 2023.** 

### Establishment of joint venture (January 26, 2023)

Invested in and commenced operations at THAI OLBA Healthcare Co., Ltd., a medical device import and sales company in Thailand

### **Reasons for expanding into Thailand**

- Economic and geographic hub-function of ASEAN region
- Expect rapid aging in the future
- Thailand government focuses on fostering the medical industry

Bridge between Japan and Thailand in the field of medical devices

• Solving Various Issues Surrounding Medical and Nursing Care



[Commemorative ceremony for the establishment of Bangkok on January 26, 2023]




[Picture of the entrance of the field office]



Using japanese technology and ideas, Establishment of a medical device production and maintenance system in Thailand<sup>6</sup>

### **Business development scheme**



TAKAZONO

Fully automated tablet packaging machine

Automatic dispensing table

agent agreement with Takazono Co., Ltd. in the Kingdom of Thailand

TACAZONO INC https://www.takazono.co.jp/index.html

With a view to expanding into ASEAN regions in the future

### Strengthening the foundations of our mainstay medical device business

#### Investment in Nozomi MedAlliance in May. 2023,



#### [Benefits]

- Ability to access overseas companies wishing to enter the Japanese medical device market
- Incubation of medical device development seeds by domestic companies also promoted





(U.S. companies)



- Collaboration with THERANOVA (Company T)
- Introduce T Ltd.'s medical devices in the U.S. and elsewhere in collaboration with OLBA

• 17 seeds commercialized in a large number of medical devices in the United States and has a private financing record of \$300 million or more

#### Medical/Engineering Collaboration-Medical/Engineering Medical-engineering collaboration Collaboration Model Participating in the Medical Equipment Sales Industry-

#### Customer network with extensive sales channel f

Cooperation with corporations, universities, and regional industry support organizations in 34 prefectures nationwide

Participation in AMED business "HealthTechHub Chu Shikoku"

Representative of R&D: Ohara Memorial Kurashiki Central Medical Organization Clinical Medicine Research Institute (Dr. Yutaka Tokumasu)

Professional personnel: Maeshima Yohei (Special Fellow, Kurashiki Chuo Medical Organization) and others

**Consulting** Market research for products **Clinical sites** Manufacturing and under development sales companies Need **Gathering development needs** Proposal for modification of prototype Support for proper use Matching · Support for utilization of Regional industry public expenditures Manufacturing Support agencies Face shield

An example of development

Imaging Service Uchiyama Industry Co.,

**Corporate** 

Ministry of Economy, Trade and Industry

# Publication of overseas leading-edge medical device information magazines

#### Overseas medical information magazine

### **Medical Globe**

**Publication: Orba Health Care Holdings** 

This publication is Kraribate Analytics

As well as Relias Media's most recent pride

From overseas medical information, trends in the medical market, hospital initiatives, information on medical device approvals,

By the Editorial Department for articles such as M&A of overseas manufacturers

Translated and edited in an easy-to-understand manner.

You can read "Now" in the overseas medical industry in a Japanese digest.



Published in October 2010



Medical Globe introduction HP

Subscribers: Medical device manufacturers, medical institutions, major pharmaceutical companies,

# Nippon Medical Manufacturing Commons MINC Association Of the "Study Group on the Latest Trends in Overseas Medical Devices"

#### On Medical Globe

Sharing and discussing information on the latest overseas medical device information among various industries

Trade and Industry, the Ministry of Health, Labour and Welfare, the Patent Office, AMED • PMDA, Physicians, manufacturers, the Ministry of Economy and our MG Editorial Department participated and exchanged views (started in 2017 Oct)



#### **SPD** business

- Acquisition of new customers and improvement of revenue
  - Develop customers in the Chugoku-Shikoku area
  - Opening of centers in Kansai area in cooperation with Kawanishi Co., Ltd,



- Wide-area sales of the Medilia inventory management system
  - Voluntary investment type at small and medium hospitals
  - Simple and accurate inventory management
  - Inexpensive billing and remote maintenance

With customer satisfaction Improve productivity



©OLBA HEALTHCARE HOLDINGS, In

### **Nursing Care Products business**

- Increase market share in existing areas
  - Strengthen customer service by enhancing follow-up system
  - Promote sales activities using ICT
- Strengthen merchandise sales and services
  - Hearing aids sales
  - Wheel repair service



- In-house construction of residential remodeling for nursing care
  - Cultivating new users
  - Providing Safety and Security Services







Wheelchair

Hearing aids

Flexible stick

#### Planning to open additional stores in the Seto Inland Area



43

## **Reference Materials**



### **Corporate Profile**

Company Name: Orba Healthcare Holdings Co., Ltd.

(Former name: Kawanishi Holdings Co., Ltd.)

Head Office 1-3, Shimo-Ishii 1-chome, Kita-ku, Okayama

Founded in May 1921

Established 1967 Oct

Representative Director and President Yohei Maeshima Kawanishi Corporation Berkmed Corp. Capital 607750000 yen Kawanishi Corporation Employees 1327 (Consolidated, as of December 31, 2023) Sansei Corporation Fiscal Year Ended June Medical equipmen Nikko Medical Mar. 2020 Listed on the First Section of the TSE **Stock Exchange** HOSNET · Japan, Inc. **SPD** 2022 Apr. Transitioned to standard market OLBA HD Nursing Care Products Life Care Co., Ltd.

Diverse business portfolio encompassing orthopedics, cardiovascular, surgical, ophthalmology, and nursing care

# **History**

May, 1921	Established Kawanishi Kikai Kikai Store in Ounji-cho, Okayama City (currently Chuo-cho, Kita-ku, Okayama City).
Sep. 1927	Associated company Kawanishi Machinery Shop reorganized and established.
Jun 1950	Reorganized and established Kawanishi Kikiten Co., Ltd.
1967 Oct	Reorganized and established Kawanishi Medical Equipment Co., Ltd.
1985 Oct	Established Life Care Co., Ltd.
Jul 1996	Established HOSNET • Japan, Inc.
1999 Jan	Merged with three companies, Kagawa Seiki Co., Ltd. and Shikoku Medical Abilities Co., Ltd. At the same time, the company changed its name to Kawanishi Co., Ltd.
2000 Dec	Listed on the Second Section of the Tokyo Stock Exchange.
2004 Jan	The business division was established as Kawanisi Co., Ltd. through a new split company. At the same time, the company name was changed to KAWANISHI Holdings Co., Ltd.
Jun 2005	Acquired 100% of the shares of Nikko Medical Materials Co., Ltd.
2012 Jan	Acquired 100% of the stock of Sansei Medical Materials Co., Ltd.
2014 Aug.	Head office moved to 1-1-3, Shimo-Ishii, Kita-ku, Okayama, in line with the expansion of the Group's business scope.
2016 Jan	Established Exora Medical Co., Ltd.
Jul 2019	EstablishedKawanishi BarcMed Co., Ltd.
2020 Mar	Listed on the Second Section of the Tokyo Stock Exchange to the First Section of the Tokyo Stock Exchange.
2021 Jan	To commemorate its 100th anniversary, the company changed its name to Orba Healthcare Holdings, Inc.
2022 Apr	Transitioned to a standard market in accordance with a review of market categories on the Tokyo Stock Exchange.
Jun 2022	Acquired 100% of the shares of Kawanishi BarcMed Co., Ltd.
2023 Jan,	Established Thailand Healthcare Co., Ltd. (THAI OLBA Healthcare Co., Ltd.) in the Kingdom of Thailand.

### **OLBA Employee Charter**

#### **Business Structure**

- o Contribute to the development of medicine, medical care, and nursing care through business and contribute to the health and longevity of the national
- o Promptly and appropriately provide patients and healthcare providers with the benefits of innovative new features and technologies
- Integrity and Continuity with Stakeholders (Customers, Business Partners, Employees, Local Communities, Shareholders)
   Providing value to focuses
- o Actively interact inside and outside the industry, foster creativity, and frontiers from a global perspective Explore

#### **Organizational Structure**

- Respect for human resource development and place emphasis on "management (through human resources)"
- o Emphasizing Diversity and Recognizing Diverse Opinions, Values, and Working Styles
- Try to compete and trade fairly at any time
- o Results from competition are reinvested to create new value
- o Develop an environment where members can be healthy both mentally and physically and have a willingness to contribute

#### **How Members Are**

- Have a willingness to grow voluntarily and independently
- o Continue to learn modestly without being comfortable with past results
- Not good at free riding to benefit without their own contributions or efforts
- Respect business partners inside and outside the company and engage in business with high ethical standards and pride

# **Consolidated Balance Sheets (2Q FY6/2024)**

**JPYmn** 

Assets	Amount	Change	
Cash and deposits	2,921	521	
Trade receivables	26,135	1,626	
Commodities	6,590	429	
Other	698	27	
Total current assets	36,344	2,603	
Tangible fixed assets	4,253	5	
Ntangible assets	704	0	
Investments and other assets	2,143	△40	
Total fixed assets	7,102	△35	
Total assets	43,446	2,568	

Liabilities and Net Assets	Amount	Change
Trade payables	26,846	1,474
Short-term debt	2,700	1,745
Other	1,738	△527
Total current liability	31,284	2,692
Long-term debt	-	0
Other	2,006	48
Total long-term liability	2,006	48
Total liabilities	33,291	2,741
Total net assets	10,155	△172
Total liability and net assets	43,446	2,568

**\*\*Change from previous year-** end

Net assets per share 1,716.62 yen

# **Consolidated Statements of Cash Flows (FY2024 2Q)**

JPYmn	FYE June 2023 2nd quarter	FYE June 2024 2nd quarter
Pre-tax profit	856	745
Depreciation	234	259
Decrease (increase) in notes and accounts receivable-trade (increase in $\Delta$ )	△834	△1,629
Decrease (increase) in inventories (increase in $\triangle$ )	△560	△429
Increase (decrease) in notes and accounts payable-trade (decrease in $\Delta$ )	△281	1,474
Other	△1,349	△565
Cash flows from operating	△1,934	△145
/tangible fixed assets Purchase	△98	△154
Intangible fixed assets Purchase	△41	△87
Loans to subsidiaries and affiliates	-	△100
Other	Δ3	Δ33
Investing Cash flows	△142	△374

# **Consolidated Statements of Cash Flows (FY2024 2Q)**

JPYmn	FYE June 2023 2nd quarter	FYE June 2024 2nd quarter
Net increase (decrease) in short-term borrowings ( $\Delta$ )	2,100	1,800
Repayments of long-term debt	△110	△55
Expense by acquisition of treasury shares	Δ181	△221
Proceeds from sales of treasury stock	175	1
Dividends paid	△367	△435
Other	△83	△76
Financial cash flow	△1,534	1,014
Net increase (decrease) in cash and cash equivalents (decrease in $\Delta$ )	△543	521
Cash and Cash Equivalents at Beginning of Year	3,149	2,359
Cash & cash equivalents at year-end	2,606	2,881

# **Consolidated Financial Data** ①

Item	Unit	2019/6	2020/6	2021/6	2022/6	2023/6
Sales	JPYmn	97,998	97,872	102,072	107,959	110,472
Operating profit	JPYmn	1,301	927	1,540	2,073	2,151
Recurring profit	JPYmn	1,309	905	1,542	2,119	2,158
Attributable to owners of the parent Net income	JPYmn	775	326	989	1,535	1,414
Net assets	JPYmn	6,771	7,281	8,131	9,093	10,327
Total assets	JPYmn	33,772	33,683	36,562	39,968	40,878
BPS	Yen	1,191.62	1,197.17	1,336.91	1,513.91	1,712.19
EPS	Yen	138.24	56.76	162.66	252.80	234.90
Equity ratio	%	19.8	21.6	22.2	22.8	25.3
ROE	%	12.0	4.7	12.8	17.8	14.6
ROA	%	3.9	2.7	4.4	5.5	5.3
PER	Times	9.77	23.85	10.17	6.63	7.70
PBR	Times	1.13	1.13	1.24	1.11	1.06

## **Consolidated Financial Data 2**

Item	Unit	2019/6	2020/6	2021/6	2022/6	2023/6
Sales CF	JPYmn	136	862	3,126	2,420	△659
Investment CF	JPYmn	△361	△496	△630	△211	Δ306
Finance CF	JPYmn	△62	439	△2,262	Δ1,169	175
Cash and cash equivalent	JPYmn	1,070	1,877	2,110	3,149	2,359
Bank loans	JPYmn	2,261	2,615	795	275	955
Number of employees	People	1,189	1,222	1,261	1,289	1,317
Medical equipment	People	868	892	913	938	955
SPD	People	163	171	177	175	177
Nursing care	People	122	120	131	135	138
import and sales	People	2	2	-	-	-
headquarters	People	34	37	40	41	47

**XImport and sales business is excluded from 2021/6.** 

### **Corporate Information/Inquiries**

[Fiscal year] From July 1 to June 30 of the following year

[Ordinary General Meeting of Shareholders] Held annually in September

[Stock Exchange Listings] Tokyo Stock Exchange (Standard Market)

Ticker 2689

[Number of shares per unit] 100 shares

【Contact Details】 Olba Healthcare Holdings, Inc.

Murata Advertising Head of Group administration a managing director division

info@olba.co.jp

TEL: +81-86-236-1115

FAX: +81-86-236-1116

- While we take all possible measures with respect to the datum provided in this material, The accuracy and completeness of information is not guaranteed.
- To the information available at the time of preparation of the data for the opinions and projections contained in the materials
- This is our outlook, and we do not compensate for any results using such opinions, forecasts, etc. The information in this document is subject to change without notice.
- This material is intended to provide a better understanding of us and is not necessarily intended as a recommendation to invest. We asked investors to make their own decisions on the final outcome of their investments.